Insider Selling: USANA Health Sciences, Inc. (USNA) Major Shareholder Sells 30,000 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) major shareholder Global Ltd Gull sold 30,000 shares of the company’s stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $114.19, for a total transaction of $3,425,700.00. Following the completion of the transaction, the insider now owns 9,971,895 shares in the company, valued at $1,138,690,690.05. The sale was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Global Ltd Gull also recently made the following trade(s):

  • On Thursday, September 6th, Global Ltd Gull sold 40,000 shares of USANA Health Sciences stock. The stock was sold at an average price of $126.74, for a total transaction of $5,069,600.00.
  • On Tuesday, August 21st, Global Ltd Gull sold 60,000 shares of USANA Health Sciences stock. The stock was sold at an average price of $131.35, for a total transaction of $7,881,000.00.
  • On Thursday, August 9th, Global Ltd Gull sold 90,000 shares of USANA Health Sciences stock. The stock was sold at an average price of $131.03, for a total transaction of $11,792,700.00.
  • On Monday, August 6th, Global Ltd Gull sold 100,000 shares of USANA Health Sciences stock. The stock was sold at an average price of $131.00, for a total transaction of $13,100,000.00.
  • On Tuesday, December 4th, Global Ltd Gull sold 6,681 shares of USANA Health Sciences stock. The stock was sold at an average price of $70.47, for a total transaction of $470,810.07.
  • On Saturday, December 1st, Global Ltd Gull sold 12,436 shares of USANA Health Sciences stock. The stock was sold at an average price of $70.45, for a total transaction of $876,116.20.
  • On Tuesday, December 11th, Global Ltd Gull bought 10,396 shares of USANA Health Sciences stock. The stock was bought at an average price of $70.70 per share, for a total transaction of $734,997.20.
  • On Saturday, December 8th, Global Ltd Gull bought 824 shares of USANA Health Sciences stock. The stock was bought at an average price of $70.70 per share, for a total transaction of $58,256.80.
  • On Thursday, December 6th, Global Ltd Gull acquired 1,200 shares of USANA Health Sciences stock. The shares were acquired at an average price of $70.70 per share, for a total transaction of $84,840.00.

Shares of NYSE USNA traded up $0.08 during midday trading on Friday, reaching $112.59. 135,200 shares of the company’s stock traded hands, compared to its average volume of 160,192. USANA Health Sciences, Inc. has a one year low of $64.20 and a one year high of $137.95. The company has a market cap of $2.83 billion, a PE ratio of 27.73 and a beta of 0.61.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, October 23rd. The company reported $1.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.14. USANA Health Sciences had a net margin of 7.57% and a return on equity of 30.37%. The firm had revenue of $296.80 million for the quarter, compared to the consensus estimate of $289.54 million. During the same period last year, the firm earned $1.03 earnings per share. The company’s quarterly revenue was up 13.4% on a year-over-year basis. As a group, equities research analysts expect that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current year.

USANA Health Sciences declared that its board has initiated a share buyback plan on Tuesday, October 23rd that allows the company to buyback $150.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 5.9% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in USNA. BlackRock Inc. boosted its stake in shares of USANA Health Sciences by 14.2% during the first quarter. BlackRock Inc. now owns 829,290 shares of the company’s stock valued at $71,237,000 after purchasing an additional 103,325 shares in the last quarter. JPMorgan Chase & Co. lifted its position in USANA Health Sciences by 112.0% during the first quarter. JPMorgan Chase & Co. now owns 42,276 shares of the company’s stock valued at $3,631,000 after acquiring an additional 22,335 shares during the last quarter. Millennium Management LLC lifted its position in USANA Health Sciences by 314.6% during the first quarter. Millennium Management LLC now owns 84,445 shares of the company’s stock valued at $7,254,000 after acquiring an additional 64,078 shares during the last quarter. Legal & General Group Plc lifted its position in USANA Health Sciences by 40.2% during the first quarter. Legal & General Group Plc now owns 5,852 shares of the company’s stock valued at $503,000 after acquiring an additional 1,678 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in USANA Health Sciences during the first quarter valued at approximately $235,000. Hedge funds and other institutional investors own 51.50% of the company’s stock.

A number of research firms have recently issued reports on USNA. Pivotal Research reiterated a “hold” rating and set a $135.00 price objective on shares of USANA Health Sciences in a research note on Wednesday, July 25th. Sidoti upgraded shares of USANA Health Sciences from a “neutral” rating to a “buy” rating in a research note on Thursday, October 25th. One analyst has rated the stock with a sell rating and three have given a buy rating to the company. USANA Health Sciences presently has an average rating of “Buy” and a consensus price target of $135.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

See Also: Why Dividend Stocks May Be Right for You

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply